Kiniksa Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Kiniksa Pharmaceuticals has been growing earnings at an average annual rate of 42.3%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 77% per year. Kiniksa Pharmaceuticals's return on equity is 3.2%, and it has net margins of 5.2%.
Key information
42.3%
Earnings growth rate
47.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 77.0% |
Return on equity | 3.2% |
Net Margin | 5.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
Jan 02Kiniksa's antibody treatment shows clinical benefit in late-stage COVID-19 study
Dec 22Dosing underway in Kiniksa Pharma's lumpy skin disease study with vixarelimab
Dec 15Kiniksa Pharma's KPL-404 shows encouraging action in early-stage study
Nov 30Kiniksa's vixarelimab nabs accelerated review in U.S. for a skin disorder
Nov 16Revenue & Expenses BreakdownBeta
How Kiniksa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 270 | 14 | 129 | 76 |
30 Sep 23 | 249 | -7 | 120 | 70 |
30 Jun 23 | 281 | 231 | 110 | 70 |
31 Mar 23 | 236 | 196 | 105 | 60 |
31 Dec 22 | 220 | 183 | 98 | 65 |
30 Sep 22 | 177 | 143 | 93 | 79 |
30 Jun 22 | 90 | -112 | 90 | 81 |
31 Mar 22 | 71 | -134 | 88 | 91 |
31 Dec 21 | 39 | -158 | 86 | 99 |
30 Sep 21 | 20 | -175 | 79 | 109 |
30 Jun 21 | 8 | -189 | 70 | 121 |
31 Mar 21 | 0 | -184 | 57 | 120 |
31 Dec 20 | 0 | -161 | 45 | 112 |
30 Sep 20 | 0 | -140 | 38 | 99 |
30 Jun 20 | 0 | -123 | 35 | 89 |
31 Mar 20 | 0 | -122 | 35 | 97 |
31 Dec 19 | 0 | -162 | 35 | 135 |
30 Sep 19 | 0 | -173 | 35 | 147 |
30 Jun 19 | 0 | -170 | 31 | 146 |
31 Mar 19 | 0 | -153 | 27 | 133 |
31 Dec 18 | 0 | -103 | 22 | 87 |
30 Sep 18 | 0 | -93 | 16 | 80 |
30 Jun 18 | 0 | -85 | 13 | 74 |
31 Mar 18 | 0 | -76 | 11 | 65 |
31 Dec 17 | 0 | -65 | 9 | 56 |
Quality Earnings: KNSA has high quality earnings.
Growing Profit Margin: KNSA's current net profit margins (5.2%) are lower than last year (83.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KNSA has become profitable over the past 5 years, growing earnings by 42.3% per year.
Accelerating Growth: KNSA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: KNSA had negative earnings growth (-92.3%) over the past year, making it difficult to compare to the Biotechs industry average (-8.9%).
Return on Equity
High ROE: KNSA's Return on Equity (3.2%) is considered low.